All In Biotech

Drug Trial Radar · NCT04505033

A Study of Injection HB0017 in Adult Healthy Volunteers

A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0017 Following a Single Dose in Adult Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Oct 2, 2020

Primary completion

Jan 2, 2021

Study completion Feb 1, 2021

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

placebo by subcutaneous (SC) administration. Forty subjects (10 subjects per cohort for SC administration) will be randomized and assigned to up to 4 sequential doses cohorts of HB0017 (50 mg, 150 mg, 300 mg and 450 mg) or matching placebo. Each cohort of ten volunteers will be randomly assigned to receive either a single dose of HB0017 or matching placebo at a ratio of 4:1. Starting with the lowest dose, each of the subsequent doses will be administered only if the preceding dose was determined to be safe and well tolerated. The decision to escalate the next dose will be made jointly by the sponsor s medical expert and the investigator based upon review of 15-day blinded safety data prior to dosing each cohort.

Conditions

  • Healthy Subjects

Interventions

  • HB0017Drug

    HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.

  • placeboDrug

    A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: 113Days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Auckland Clinical Studies Ltd

    Grafton, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.